Melisa Masuda-Herrera

Potential impurities in drug substances: Compound-specific toxicology limits for 20 synthetic reagents and by-products, and a class-specific toxicology limit for alkyl bromides

Joel P. Bercu, Sheila M. Galloway, Patricia Parris et al. · Regulatory Toxicology and Pharmacology · 2018 · 47 citations

Pharmacy, Pharmaceutical Analysis, Toxicology +14

Acceptable intakes (AIs) for 11 small molecule N-nitrosamines (NAs)

Joel P. Bercu, Melisa Masuda-Herrera, Alejandra Trejo‐Martin et al. · Regulatory Toxicology and Pharmacology · 2023 · 32 citations · Full text

Pharmacy, Pharmacology, Toxicology +10

A cross-industry collaboration to assess if acute oral toxicity (Q)SAR models are fit-for-purpose for GHS classification and labelling

Joel P. Bercu, Melisa Masuda-Herrera, Alejandra Trejo‐Martin et al. · Regulatory Toxicology and Pharmacology · 2020 · 29 citations · Full text

Pharmacy, Toxicology, Drug Discovery +15

Use of less-than-lifetime (LTL) durational limits for nitrosamines: Case study of N-Nitrosodiethylamine (NDEA)

Joel P. Bercu, Melisa Masuda-Herrera, George E. Johnson et al. · Regulatory Toxicology and Pharmacology · 2021 · 26 citations · Full text

Medicine, Pharmacology, General Pharmacology +5

Principles and procedures for assessment of acute toxicity incorporating in silico methods

Craig Zwickl, Jessica Graham, Robert A. Jolly et al. · Computational Toxicology · 2022 · 26 citations · Full text

Pharmacy, Toxicology, Mechanisms Of Toxicity +7